PL04.07 FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations
Recommended Citation
Le X, Yu Y, Zhao Y, Planchard D, Cheng Y, Li X, Gadgeel SM, Zhang J, Spira A, Hayashi H, Riess J, Kitazono S, Leighl N, Gao B, Juan-Vidal O, de Langen AJ, Mazieres J, Pérol M, Jiang Y, Hu T, Huang J, Baio N, Musib L, Kowanetz M, Wang S, Leung W, Yea S, Hsu J, Wang J. PL04.07 FURTHER: A Global, Randomized Study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations. J Thorac Oncol 2024; 19(10):S5-S6.
Document Type
Conference Proceeding
Publication Date
9-9-2024
Publication Title
J Thorac Oncol
Abstract
Firmonertinib (also known as furmonertinib) is an oral, highly brain-penetrant EGFR inhibitor with broad activity and selectivity across EGFR mutations. Firmonertinib is approved in China for first-line, advanced NSCLC with EGFR Ex19del/L858R and previously treated advanced NSCLC with EGFR T790M. Firmonertinib has received FDA Breakthrough Therapy Designation for first-line, advanced NSCLC with EGFR ex20ins mutations. P-loop and αC-helix compressing (PACC) mutations represent approximately 12% of EGFR mutations and are similar to ex20ins mutations in narrowing the drug-binding pocket of ATP competitive EGFR inhibitors (Robichaux et al, 2021). Firmonertinib is potent in cell lines harboring EGFR PACC and ex20ins mutations and inhibits tumor growth at doses in PDX models that are clinically relevant (Musib et al, 2022; Nilsson et al, 2024).
Volume
19
Issue
10
First Page
S5
Last Page
S6
